Bydureon (Exenatide): Side Effects, Uses, Dosage, Interactions ... - RxList
网页Following a single dose of BYDUREON, exenatide is released from the microspheres over approximately 10 weeks. There is an initial period of release of surface-bound exenatide followed by a gradual release of exenatide from the microspheres, which results in two subsequent peaks of exenatide in plasma at around Week 2 and Week 6 to 7 ...
Exenatide Microspheres for Monthly Controlled-Release Aided …
网页2021年5月30日 · Among GLP-1 receptor agonists, exenatide is the one requiring the least dose so that controlled-release poly(d, l-lactic-co-glycolic acid) (PLGA) microspheres may best achieve this purpose.
Exenatide Microspheres for Monthly Controlled-Release Aided …
网页2021年5月30日 · Among GLP-1 receptor agonists, exenatide is the one requiring the least dose so that controlled-release poly(d, l-lactic-co-glycolic acid) (PLGA) microspheres may best achieve this purpose.
Bydureon BCise (exenatide) - Uses, Side Effects, and More - WebMD
网页2024年6月25日 · Common Generic Name (s): exenatide; exenatide extended-release injectable suspension; exenatide microspheres. Pronunciation: by-DUR-ee-on B-cise. Drug Classes: antidiabetic; GLP-1 agonist;...
Exenatide Microspheres for Monthly Controlled-Release Aided …
网页2021年5月30日 · This formulation strategy was successfully applied to produce PLGA microspheres of exenatide. The pharmacokinetic study on monkeys and the efficacy study on mice indicate that the exenatide microspheres by the present formulation may offer prolonged efficacy (once in a month) with reduced dose and lowered C MAX, implying reduced side effects ...
Long-acting preparations of exenatide - PMC - National Center …
网页2013年9月5日 · Microspheres are a stable and seasoned way of achieving SR for peptides such as exenatide (Table 1).14–16 The safety, reliability, and efficiency of microspheres have been well established over the years. Currently, the only long-acting exenatide product on the market in microsphere form is Bydureon™ (Amylin Pharmaceuticals).
Exenatide Monograph for Professionals - Drugs.com
网页2023年10月16日 · Following sub-Q administration of extended-release exenatide, drug is released from the microspheres over approximately 10 weeks. Initial release of surface-bound exenatide is followed by gradual release from microspheres; peak concentrations occur at approximately week 2 and week 6–7.
Exenatide loaded PLGA microspheres for long-acting …
网页2016年4月11日 · Optimized exenatide-loaded microspheres were endowed with high entrapment efficiency (83.8 ± 1.3%) and low initial burst release (1.31 ± 0.13%). Degradation pattern of the peptide-loaded microspheres was investigated by monitoring the changes in molecular weight, appearance, and release profile.
网页exenatide is the one requiring the least dose so that controlled-release poly(D,L-lactic-co-glycolic acid) (PLGA) microspheres may best achieve this purpose. Based on this consideration, the present study extended the injection interval of exenatide microspheres from one week of the current dosage
Exenatide extended-release: a once weekly treatment for patients …
网页2014年6月24日 · Exenatide ER is a glucagon-like peptide-1 (GLP-1) receptor agonist, the third to be approved in the US, and is associated with a low risk of hypoglycemia, may result in weight loss, and has proven to be a safe and effective treatment for T2DM. Exenatide ER reduces A 1c levels by decreasing fasting and postprandial hyperglycemia. The …
- 某些结果已被删除